On Monday, Oracle Corporation (NYSE:ORCL)’s shares inclined 1.25.% to $36.83.
Oracle Corporation (ORCL) declared fiscal 2016 Q1 results. The strengthening of the U.S. dollar contrast to foreign currencies had a significant impact on results in the quarter. Total Revenues were $8.4 billion, down 2% in U.S. dollars but up 7% in constant currency. Cloud plus On-Premise Software Revenues were $6.5 billion, down 2% in U.S. dollars and up 6% in constant currency. Total Cloud Revenues were $611 million, up 29% in U.S. dollars and up 34% in constant currency. Cloud software as a service (SaaS) and platform as a service (PaaS) revenues were $451 million, up 34% in U.S. dollars and up 38% in constant currency. Cloud infrastructure as a service (IaaS) revenues were $160 million, up 16% in U.S. dollars and up 23% in constant currency. Total On-Premise Software Revenues were $5.8 billion, down 4% in U.S. dollars but up 4% in constant currency. Total Hardware Revenues were $1.1 billion, down 3% in U.S. dollars but up 6% in constant currency. Total Services Revenues were $862 million, up 1% in U.S. dollars and up 10% in constant currency.
Operating Income was $2.7 billion and Operating Margin was 31%. Non-GAAP Operating Income was $3.5 billion and non-GAAP Operating Margin was 41%. Net Income was $1.7 billion while non-GAAP Net Income was $2.3 billion. Earnings Per Share was $0.40, while non-GAAP Earnings Per Share was $0.53. Without the impact of the U.S. dollar strengthening contrast to foreign currencies, Oracle’s stated Q1 GAAP and non-GAAP Earnings Per Share would have been 6 cents higher.
Oracle Corporation develops, manufactures, markets, sells, hosts, and supports database and middleware software, application software, cloud infrastructure, hardware systems, and related services worldwide.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s shares gained 0.23% to $8.71.
Achillion Pharmaceuticals, Inc. (ACHN) declared additional interim results from a Phase 2 study evaluating odalasvir (also known as ACH-3102), a NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for either six or eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus (HCV) infection. Of the patients treated for six weeks in this cross-over cohort, 100 percent (n=6/6) remained HCV RNA undetectable twelve weeks after concluding therapy (SVR12). Formerly, Achillion stated results from this study counting 100 percent SVR24 for the initial cohorts counting 12 patients treated for eight weeks and 100 percent SVR24 for 12 patients treated for six weeks.
In May 2015, Achillion declared it had granted Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion’s HCV assets which comprise odalasvir, ACH-3422, and sovaprevir.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections.
At the end of Monday’s trade, Gentex Corporation (NASDAQ:GNTX)‘s shares surged 0.57% to $15.92.
Gentex Corporation (GNTX) — Seeing what’s behind you is critical to safe driving, whether you’re in a passenger vehicle or one of the most technologically advanced racecars in the world. A new pioneering technology designed to improve rear vision recently took a step closer to reality after successfully debuting at the grueling 24 Hours of Le Mans on Nissan’s new GT-R LM NISMO race car. The system comprises of a tiny rearward-facing camera that feeds live video to a mirror-integrated display in order to optimize a vehicle’s rearward view.
Gentex Corporation, a leading supplier of vision-related technologies to the global automotive industry, developed the technology. The system was originally designed for application on passenger vehicles; however, the Company recently formed a partnership with the Nissan Motorsports Team, which allowed the system to be installed on Nissan’s new LM P1 race cars and thoroughly vetted under demanding race conditions.
Gentex Corporation designs, develops, manufactures, and markets automatic-dimming rearview mirrors and electronics for the automotive industry; dimmable aircraft windows for the aviation industry; and commercial smoke alarms and signaling devices for the fire protection industry worldwide.
Citizens Financial Group Inc (NYSE:CFG), ended its Monday’s trading session with 0.63% gain, and closed at $23.90.
Citizens Financial Group (CFG) declared its plans to release third quarter 2015 results on Friday, October 23 at 7:00 am ET.
Citizens Financial Group, Inc. operates as the bank holding company for Citizens Bank, N.A. and Citizens Bank of Pennsylvania that provide retail and commercial banking products and services in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
